Update on the Fight Against Cancer

Here's some good news from the front of the war on cancer, specifically Leukemia. Leukemia occurs as a result of blood cells, usually white blood cells, mutating and reproducing out of control and crowding other cells to the point that they can't function properly. Treatment often consists of using a drug called Gleevec which binds with an enzyme in cancerous cells thereby interfering with their growth and proliferation. Unfortunately, some of the cancerous leukocytes mutate so fast that the Gleevec can't wipe them out.

Now a new drug has been developed which is able to attach to many of the cells that Gleevec misses:

The new drug is being tested in patients with chronic myeloid leukemia, which affects about 4,400 Americans a year and 10,000 people around the world. The drug is known by its experimental name BMS-354825. During the trial, also financed by Bristol-Myers, 31 of 36 patients with advanced CML who had not been helped by Gleevec had a complete hematologic response, meaning their bodies stopped producing leukemia cells.

This is a good illustration of why government must not take the profit out of drug R&D by imposing onerous regulations and unreasonable caps. Companies like Bristol-Myers have to have the economic incentive to create these products or else they'll simply stop working on them. It would be nice if we lived in a world where everyone was motivated by love and research had no cost associated with it, but we don't. So perhaps we can live in a world where lawyers can't sue drug manufacturers out of business or cause the manufacturer's insurance premiums to go so high that the average person can't buy the drugs or can't buy their own insurance to pay for the drugs.